With toilet paper sold out everywhere, these are the days when you wish that Cynata was still dealing with disposable nappies
http://www.timboreham.com/wp/cynata-therapeutics/We'd be rolling in it right now, no doubt...
Interesting enough, the above article was written in February 2018, which marks also the last time we finished at today's close ($0.80 on 06/02/18).
To put that a bit into perspective:
06/02/18 closed at $0.8027/02/18 Excellent Data from Final Preliminary Evaluation Period
28/03/18 FDA Grants Orphan Drug Designation to Cyanta for CYP-001
07/05/18 Becoming a substantial holder [Fidelity]
24/05/18 Enrolment Completed in Cynata's Phase 1 Clinical Trial
30/05/18 $5.2m placement of shares to Fidelity International
31/05/18 Cynata's MSCs Effective in Model of Diabetic Wounds
07/06/18 Change in substantial holding
12/06/18 Positive 6-Month Data from Cohort 1 in Phase 1 Trial in GvHD
21/06/18 Positive 28-day Clinical Trial Data in Cohort B
31/07/18 Cymerus MSCs improve cardiac recovery in preclinical study
30/08/18 Cynata GvHD Trial Meets all Safety & Efficacy Endpoints
03/09/18 Cynata Advances to Official Meeting with Japanese PMDA
19/09/18 Cynata MSCs Ameliorate CRS in Preclinical Study
18/10/18 MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical Studies
13/12/18 NHMRC Funding for Osteoarthritis Trial Using Cymerus MSCs
18/12/18 Cynata Completes Clinical Study Report in GvHD
25/02/19 Further Cynata Asthma Study Published
04/03/19 Positive Pre-Clinical Coronary Artery Disease Data for CYP
11/03/19 Joint Study of Cynata MSCs receives VMRAF Funding
19/07/19 Cynata confirms receipt of indicative non-binding proposal [$2, Sumitomo Dainippon Pharma]
15/08/19 Update on Discussions with Sumitomo and Fujifilm
04/09/19 Cynata transplant rejection study accepted for publication
17/09/19 Fujifilm Exercises License Option in GvHD
26/09/19 Cynata Receives US$3 million Fujifilm License Fee
17/10/19 Cynata & Sumitomo Withdraw from Acquisition Discussions
28/10/19 Cynata Awarded Grant for Coronary Artery Disease Study
25/11/19 CYP Files Application to Commence Phase 2 CLI Clinical Trial
05/12/19 Cymerus MSCs Effective in Preclinical Model of Sepsis
14/01/20 Cynata Receives UK Regulatory Approval for CLI Trial
09/03/20 closed at $0.805Based on the SP, all (positive) announcements above are currently valued at $0.005.To finish off this post, the author of the above nappies post had the following to say last night:
Stem cell therapy to the rescue?
The South China Morning Post reports that a 65-year-old woman on her COVID-19 deathbed walked out of China’s Kunming Hospital after being given a stiff shot of mesenchymal stem cells (MSCs).
Two trials are also underway to test the therapy against pneumonia, at a Beijing Military Hospital and Zhongnan Hospital of Wuhan University (yep, in the coronavirus capital).
Could the excitement rub-off on our ASX-listed plays Mesoblast (ASX:MSB), Cynata Therapeutics (ASX:CYP), Orthocell (ASX:OCC) and Regeneus (ASX:RGS)?
Cynata’s Dr Ross Macdonald says the reports look authentic; and he believes that MSCs could be an effective adjunct in managing patients with serious issues pertaining to COVID-19.
“This is not because MSCs are inherently anti-viral or can act as a vaccine, but more because they have shown benefit in major pathologies associated with infection,” he says.
Cynata, we stress, has not mentioned coronavirus in its dispatches and nor has any of the other non-China MSC plays — or not yet anyway.
But still, what decent CEO would not give his company a plug?
“The clear advantage of (Cynata’s) Cymerus technology (is) the ability to make large quantities of consistent, robust MSCs without having to find gazillions of donors,” Dr Macdonald says.
https://unauthorised investment advice/health/dr-borehams-crucible-the-small-cap-biotechs-trying-to-make-a-buck-from-coronavirus/
(20min delay)